Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Non-Tech : NIFTY NINE IN NINETY NINE PLUS ONE -- Ignore unavailable to you. Want to Upgrade?

To: Arthur Radley who wrote (547)	7/8/1999 6:17:00 PM
From: Biomaven	Respond to of 613

TD: There was an article & editorial in this week's NEJM comparing Botulinum toxin and nitroglycerine in anal fissures. Botox worked better, but maybe people were reminded that nitro works too. Peter

To: Arthur Radley who wrote (547)	7/9/1999 12:02:00 AM
From: Scott H. Davis	Read Replies (1) \| Respond to of 613

Dude, Congrads on Xoma, To several of us, looks like AXPH is suddenly moving. Perhaps several of us were very frustrated between the disconnect between clinical/business case developments vs price and broad market. Congrads to those who stuck it out. With AXC, ADIC & PTIX (plus IMCL, MLNM, & HLIT which I gave up on too soon, at a profit yet a meager profit vs today) these have ultimately rewarded longs who stuck with these while the long term fundimentals remained intact, despite short term issues) I hope VICL & ISIP will have their day in the sun. Especially VICL, as I know of not other biotech that has a better risk/reward profile. I anyone has a better case, I'd love to hear it. Scott